Articles by Zachary Bessette
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Cabozantinib continues to demonstrate significant improvement in PFS in extra-pancreatic or pancreatic neuroendocrine tumors.
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
The CodeBreaK 101 study assessed the safety and efficacy of soto, pani, and FOLFIRI for KRAS G12C-mutated mCRC.
STRIDE shows “unprecedented” 5-year survival benefit, with no additional serious safety events, for patients with uHCC.
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
The latest data from the RECAST trial shed light on FOLFIRI plus RAM for patients with metastatic CRC.
A phase 2 trial comparing DEB-TACE with irinotecan, mitomycin C vs DEB-TACE with doxorubicin for intermediate-stage HCC.
FOLFOX-HAIC plus sintilimab and IBI305 demonstrates promising safety and efficacy in uHCC, Child-Pugh B liver function.
The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.
Integrated PET/MRI may be superior to PET/CT in diagnosing malignant tumor liver metastasis/lymphoma hepatic infiltration.
Neoadjuvant pembrolizumab may be effective and safe for early-stage dMMR/MSI-high colorectal cancer.
The ORCHESTRA trial does not support additional tumor debulking to improve OS for patients with multiorgan mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.